Polypectomized Patients
Conditions
Keywords
Beta-glucan, faecal microflora, polypectomized, Precancerous Nonmalignant Condition
Brief summary
The aim of this study is to determine the effect of the potential prebiotic beta-glucan on the intestinal microflora, the bacterial enzyme activity (beta-glucuronidase and beta-glucosidase) in the feces, the fecal pH and the concentration of fecal short-chain fatty acid in polypectomized patients. Also the in vitro anti-cyto- and anti-genotoxicity of fecal water will be examined on human cell culture (HT29). During the trial, patient's clinical symptoms (intestinal habits), physical activity, well-being and food intake will be recorded.
Detailed description
Prebiotics, such as short- and long-chain fructo-oligosaccharides are fermented by the microflora colonizing the gastrointestinal tract, and they selectively stimulate the growth or the activity of one or limited number of bacteria within the intestine. Beta-glucans are polysaccharides occurring in the bran of cereal grains, the cell wall of Saccharomyces cerevisiae and bacteria, certain types of fungi, seaweed and many kinds of mushrooms. The aim of this study is to determine the effect of the potential prebiotic beta-glucan on the intestinal microflora, the bacterial enzyme activity (beta-glucuronidase and beta-glucosidase) in the faeces, the faecal pH, and the concentration of faecal short-chain fatty acid in polypectomized patients.
Interventions
DIETARY_SUPPLEMENTwheat bread with beta-glucan
3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months
DIETARY_SUPPLEMENTwheat bread without beta-glucan
Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months
Sponsors
JOTIS S.A. FOOD INDUSTRY, GREECE
Harokopio University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* The subjects must have biopsy and histologically confirmed adenomatous polyps ≥ 1cm in size or ≥ 3 in number with moderate or severe dysplasia
Exclusion criteria
* Subjects ≥ 75 years of age * Subjects who are pregnant or desire to become pregnant during the study period * Subjects who are considered to be poor clinic attendees * Subjects who have been on antibiotics within the previous month or are likely to require antibiotics during the trial * Subjects who consume prebiotics or probiotics within the previous month or are likely to require antibiotics during the trial * Subjects with colon cancer * Subjects with additional gastrointestinal disorders (e.g., Crohn's disease or ulcerative colitis) * Subjects with malignancy or any end-stage organ disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To measure the effect of beta-glucan on fecal microflora (number of bacteria, bacterial enzyme activity, SCFA, pH). | four months |
| To observe the effect of beta-glucan on intestinal symptoms and well-being. | four months |
Secondary
| Measure | Time frame |
|---|---|
| To study the fecal water cyto- and/or genotoxicity on HT-29 cell line. | one year |
Countries
Greece
Outcome results
None listed